MMP12 and triple-A syndrome: Subramanian et al. (48) later conducted in vivo pharmacological inhibition of a novel calpain inhibitor, BDA-410, which successfully reduced the incidence and development of AAA by attenuating the activation of MMP12, pro-inflammatory cytokines, and macrophage infiltration into the aorta using similar AAA mice models.